Tacrolimus population pharmacokinetic-pharmacogenetic analysis and bayesian estimation in renal transplant recipients

Clinical Pharmacokinetics

Volumn 48, Issue 12, 2009, Pages 805-816

  Benkali, Khaled ^a   Prémaud, Aurelie ^a   Picard, Nicolas ^a   Rérolle, Jean Philippe ^b   Toupance, Olivier ^c   Hoizey, Guillaume ^c   Turcant, Alain ^d   Villemain, Florence ^d   Le Meur, Yannick ^a,e   Marquet, Pierre ^a   Rousseau, Annick ^a,f  

^a Univ Limoges   (France)

^b LIMOGES UNIVERSITY HOSPITAL   (France)

^c REIMS UNIVERSITY HOSPITAL   (France)

^d ANGERS UNIVERSITY HOSPITAL   (France)

^e BREST UNIVERSITY HOSPITAL   (France)

^f UNIVERSITY OF LIMOGES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREGNANE X RECEPTOR; TACROLIMUS;

ADULT; AGED; ALLELE; AREA UNDER THE CURVE; ARTICLE; BAYES THEOREM; CLINICAL ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; DNA POLYMORPHISM; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; FEMALE; GENOTYPE; HEMATOCRIT; HUMAN; KIDNEY TRANSPLANTATION; MALE; PHARMACOGENETICS; POPULATION RESEARCH; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; ALLELES; AREA UNDER CURVE; BAYES THEOREM; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FRANCE; GENE FREQUENCY; GENOTYPE; HEMATOCRIT; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MODELS, STATISTICAL; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; POPULATION; RECEPTORS, STEROID; SOFTWARE; TACROLIMUS; YOUNG ADULT;

EID: 70449368823     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/11318080-000000000-00000     Document Type: Article

References (33)

1. Venkataramanan R, Swaminathan A, Prasad T, et al. Clinical pharmaco-kinetics of tacrolimus. Clin Pharmacokinet 1995 Dec; 29 (6): 404-430
2. Tada H, Satoh S, Iinuma M, et al. Chronopharmacokinetics of tacrolimus in kidney transplant recipients: occurrence of acute rejection. J Clin Pharmacol 2003 Aug; 43 (8): 859-865
3. Wong KM, Shek CC, Chau KF, et al. Abbreviated tacrolimus area-under-the-curve monitoring for renal transplant recipients. Am J Kidney Dis 2000 Apr; 35 (4): 660-666
4. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glyco-protein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 1997 Sep 15; 27 (2-3): 201-214
5. Saeki T, Ueda K, Tanigawara Y, et al. Human P-glycoprotein transports cy-closporin A and FK506. J Biol Chem 1993 Mar 25; 268 (9): 6077-6080
6. Hesselink DA, van Schaik RH, van der Heiden I, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003 Sep; 74 (3): 245-254
7. Uesugi M, Masuda S, Katsura T, et al. Effect of intestinal CYP3A5 on post-operative tacrolimus trough levels in living-donor liver transplant recipients. Pharmacogenet Genomics 2006 Feb; 16 (2): 119-127
8. Fredericks S, Moreton M, Reboux S, et al. Multidrug resistance gene-1 (MDR-1) haplotypes have a minor influence on tacrolimus dose requirements. Transplantation 2006 Sep 15; 82 (5): 705-708
9. Bertilsson G, Heidrich J, Svensson K, et al. Identification of a human nuclear receptor defines a new signaling pathway for CYP3A induction. Proc Natl Acad Sci U S A 1998 Oct 13; 95 (21): 12208-12213
10. Moore JT, Kliewer SA. Use of the nuclear receptor PXR to predict drug in-teractions. Toxicology 2000 Nov 16; 153 (1-3): 1-10
11. Pascussi JM, Drocourt L, Gerbal-Chaloin S, et al. Dual effect of dex-amethasone on CYP3A4 gene expression in human hepatocytes: sequential role of glucocorticoid receptor and pregnane X receptor. Eur J Biochem 2001 Dec; 268 (24): 6346-6358
12. Lamba J, Lamba V, Strom S, et al. Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 2008 Jan; 36 (1): 169-181
13. Zhang J, Kuehl P, Green ED, et al. The human pregnane X receptor: genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 2001 Oct; 11 (7): 555-572
14. Miura M, Satoh S, Inoue K, et al. Influence of CYP3A5, ABCB1 and NR1I2 polymorphisms on prednisolone pharmacokinetics in renal transplant recipients. Steroids 2008 Oct; 73 (11): 1052-1059
15. Fukudo M, Yano I, Yoshimura A, et al. Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients. Pharmacogenet Genomics 2008 May; 18 (5): 413-423
16. Li D, Lu W, Zhu JY, et al. Population pharmacokinetics of tacrolimus and CYP3A5, MDR1 and IL-10 polymorphisms in adult liver transplant patients. J Clin Pharm Ther 2007 Oct; 32 (5): 505-515
17. Le Meur Y, Djebli N, Szelag JC, et al. CYP3A5*3 influences sirolimus oral clearance in de novo and stable renal transplant recipients. Clin Pharmacol Ther 2006 Jul; 80 (1): 51-60
18. Boekmann AJ, Sheiner LB, Beal SL. NONMEM user's guide, part V: in-troductory guide. San Francisco (CA): NONMEM Project Group, University of California, 1992
19. Saint-Marcoux F, Knoop C, Debord J, et al. Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Clin Pharmacokinet 2005; 44 (12): 1317-1328
20. Etienne MC, Chatelut E, Pivot X, et al. Co-variables influencing 5-fluorouracil clearance during continuous venous infusion: a NONMEM analysis. Eur J Cancer 1998 Jan; 34 (1): 92-97
21. Parke J, Holford NH, Charles BG. A procedure for generating bootstrap samples for the validation of nonlinear mixed-effects population models. Comput Methods Programs Biomed 1999 Apr; 59 (1): 19-29
22. Ishibashi T, Yano Y, Oguma T. Population pharmacokinetics of platinum after nedaplatin administration and model validation in adult patients. Br J Clin Pharmacol 2003 Aug; 56 (2): 205-213
23. Premaud A, Le MY, Debord J, et al. Maximum a posteriori Bayesian esti-mation of mycophenolic acid pharmacokinetics in renal transplant recipients at different postgrafting periods. Ther Drug Monit 2005 Jun; 27 (3): 354-361
24. Sheiner LB, Beal SL. Some suggestions for measuring predictive performance. J Pharmacokinet Biopharm 1981 Aug; 9 (4): 503-512
25. Scholten EM, Cremers SC, Schoemaker RC, et al. AUC-guided dosing of tacrolimus prevents progressive systemic overexposure in renal transplant recipients. Kidney Int 2005 Jun; 67 (6): 2440-2447
26. Rousseau A, Leger F, Le Meur Y, et al. Population pharmacokinetic modeling of oral cyclosporin using NONMEM: comparison of absorption pharmaco-kinetic models and design of a Bayesian estimator. Ther Drug Monit 2004 Feb; 26 (1): 23-30
27. Djebli N, Rousseau A, Hoizey G, et al. Sirolimus population pharmacokine-tic/pharmacogenetic analysis and Bayesian modelling in kidney transplant recipients. Clin Pharmacokinet 2006; 45 (11): 1135-1148
28. Staatz CE, Willis C, Taylor PJ, et al. Population pharmacokinetics of tacrolimus in adult kidney transplant recipients. Clin Pharmacol Ther 2002 Dec; 72 (6): 660-669
29. Antignac M, Barrou B, Farinotti R, et al. Population pharmacokinetics and bioavailability of tacrolimus in kidney transplant patients. Br J Clin Pharmacol 2007 Dec; 64 (6): 750-757
30. Tunblad K, Lindbom L, McFadyen L, et al. The use of clinical irrelevance criteria in covariate model building with application to dofetilide pharma-cokinetic data. J Pharmacokinet Pharmacodyn 2008 Oct; 35 (5): 503-526
31. Undre NA, Schafer A. Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. Transplant Proc 1998 Jun; 30 (4): 1261-1263
32. Andrews WS, Sommerauer J, Conlin C, et al. Comparison of cyclosporine-vs tacrolimus-based immunosuppression in pediatric liver transplantation. Transplant Proc 1996 Apr; 28 (2): 897-898
33. Thervet E, Anglicheau D, King B, et al. Impact of cytochrome p450 3A5 genetic polymorphism on tacrolimus doses and concentration-to-dose ratio in renal transplant recipients. Transplantation 2003 Oct 27; 76 (8): 1233-5